Cambrex Corporation (NYSE:CBM) – Investment analysts at First Analysis dropped their Q4 2017 earnings per share estimates for shares of Cambrex Corporation in a research report issued to clients and investors on Monday. First Analysis analyst S. Schwartz now anticipates that the biotechnology company will post earnings per share of $1.11 for the quarter, down from their previous forecast of $1.18. First Analysis also issued estimates for Cambrex Corporation’s Q1 2018 earnings at $0.47 EPS, Q3 2018 earnings at $0.56 EPS and FY2018 earnings at $2.90 EPS.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.08. The business had revenue of $112.60 million for the quarter, compared to analysts’ expectations of $108.44 million. Cambrex Corporation had a net margin of 18.79% and a return on equity of 23.42%. The business’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.47 earnings per share.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/11/15/q4-2017-earnings-estimate-for-cambrex-corporation-issued-by-first-analysis-cbm.html.
A number of other equities analysts have also recently issued reports on the stock. BidaskClub cut shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. ValuEngine cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex Corporation in a research report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $62.33.
Shares of Cambrex Corporation (NYSE CBM) opened at $45.50 on Wednesday. The company has a market cap of $1,504.49, a price-to-earnings ratio of 14.48 and a beta of 2.26. Cambrex Corporation has a 1 year low of $42.55 and a 1 year high of $62.95.
Several hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Cambrex Corporation during the 3rd quarter worth approximately $453,000. Highbridge Capital Management LLC purchased a new stake in shares of Cambrex Corporation during the 3rd quarter worth approximately $238,000. Oppenheimer Asset Management Inc. increased its stake in shares of Cambrex Corporation by 5.1% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,737 shares of the biotechnology company’s stock worth $1,856,000 after purchasing an additional 1,625 shares during the last quarter. Synovus Financial Corp purchased a new position in Cambrex Corporation in the 3rd quarter valued at approximately $540,000. Finally, Envestnet Asset Management Inc. grew its stake in Cambrex Corporation by 37.5% in the 3rd quarter. Envestnet Asset Management Inc. now owns 17,623 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 4,803 shares in the last quarter.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares in the company, valued at approximately $4,799,546.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Steven M. Klosk sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $51.53, for a total transaction of $618,360.00. Following the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. Company insiders own 2.48% of the company’s stock.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.